MM Pharma and Healthcare Packaging has signed a major licensing deal with leading nanomaterials developer, Advanced Material Development Limited (AMD).
The agreement between the companies will see AMD’s TempSight Time Temperature Indicator (TTI) technology used to provide simple, easy-to-manufacture and cost-effective Vaccine Vial Monitor (VVM) systems.
The solution utilises AMD’s proprietary Photonic Crystal-based ‘nLight’ technology, developed in partnership with the University of Surrey, to equip its pharmaceutical packaging with advanced safety features.
These VVMs strengthen security across the supply chain and are designed to meet World Health Organization requirements around the safe transportation, distribution and delivery of vaccines.
MM and AMD intend to further develop the technology to protect a broad range of drugs and other pharmaceutical products requiring temperature-sensitive care.
John Lee, CEO at AMD, said: “We are proud to partner with MM Pharma and Healthcare Packaging to bring our TempSight Time Temperature Indicator technology to the pharmaceutical packaging industry."
"This collaboration marks a significant step forward in enhancing vaccine safety for patients, providing robust supply chain security and confidence in temperature-sensitive vaccine delivery."
"We look forward to working with the team as they continue advancing patient safety and supply chain integrity worldwide.”
Tiffany Overstreet, Global Innovation Director at MM Pharma and Healthcare Packaging, said: "Our partnership with AMD marks a milestone in our commitment to providing packaging that protects patients and supply chain security alike."
"Integrating AMD’s advanced technology means that we can offer our customers cost-effective and reliable solutions for monitoring temperature-sensitive treatments, including vaccines, throughout the supply chain."
"MM Pharma and Healthcare Packaging continues to lead the industry by driving advancements that ensure the highest quality and safety in pharmaceutical delivery worldwide.”